CT103A cells

Phase 1Biologic

TTongji Hospital

CT103A cells is one of 3 biologic programs targeting Inflammatory Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory DiseaseRecruiting

Inflammatory DiseasePhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Inflammatory Disease

#DrugCompanyPhaseTrials

Jyseleca

Gilead

Phase 2

1 2

CT103A cells

TTongji Hospital

Phase 1

1 3

Cyclophosphamide and Fludarabine

TTongji Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Inflammatory Disease

NCT04561557

Clinical

Trials by Indication[1]

Inflammatory Disease1 trial

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Recruiting·TTongji Hospital·Phase 1·NCT04561557·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CT103A cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CT103A cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CT103A cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TTongji Hospital

CT103A cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Inflammatory Disease1 trial

References

Drug Info

Quick Facts

Related News